{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:32:52Z","timestamp":1762428772695,"version":"build-2065373602"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Identify factors associated with the engraftment of gastric cancer patient-derived xenograft (GC PDX) in the renal capsule and explore optimal MRI sequence parameters for observing renal capsule PDX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Tumor tissues from 33 gastric cancer patients were cut into fragments of 1\u00d71\u00d71 mm, 2\u00d72\u00d72 mm, and 3\u00d73\u00d73 mm, then transplanted beneath the renal capsule of NOD\/SCID mice within 2, 8 and 24 hours. Depending on tissue availability, tumor samples from each patient were implanted into 1\u20134 mice, totaling 73 mice. Clinical data were collected. Tumor growth was monitored weekly via MRI. T1WI, contrast-enhanced T1WI, T2WI was used to measure tumor length. After euthanasia (10g\/L sodium pentobarbital, 180mg\/kg, intraperitoneal), tumors were excised, and caliper-measured were compared with MRI results. The xenografts were serially passage into new mice for three generations. Histopathological (H&amp;amp;E), Ki67 immunohistochemistry were performed to assess similarity with primary tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Tumors from 20 out of 33 patients successfully engrafted in 28 out of 73 mice. The 2\u00d72\u00d72 mm grafts and transplantation in 2 hours had a higher success rate. Patient serum albumin was associated with successful engraftment. PDX exhibited isointense and hyperintense on T2WI and marked enhancement on T1WI post-contrast. No significant difference was observed between MRI and caliper-measured. H&amp;amp;E staining, Ki67 expression confirmed that PDX tumors retained histological features of primary tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Optimal conditions for establishing GC PDX models involve transplanting 2\u00d72\u00d72 mm tumor fragments within 2 hours. MRI enables sensitive tumor detection and accurate size quantification. T2WI was the most effective and efficient imaging technique. Providing an efficient preclinical model for personalized therapy of gastric cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1683916","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:12:00Z","timestamp":1762351920000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Renal capsule patient-derived xenograft model for gastric cancer: establishment and MRI characterization"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhenyu","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewetse Paul","family":"Maswikiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuanfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.3390\/ijms21114012","article-title":"Gastric cancer: Epidemiology, risk factors, classification, genomic characteristics and treatment strategies","volume":"21","author":"Machlowska","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00297-7","article-title":"Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial","volume":"22","author":"Zhang","year":"2021","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/0300060519827191","article-title":"Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma","volume":"47","author":"Lu","year":"2019","journal-title":"J Int Med Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12516","article-title":"The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-015-9611-y","article-title":"The role of hypoxia and cancer stem cells in renal cell carcinoma pathogenesis","volume":"11","author":"Myszczyszyn","year":"2015","journal-title":"Stem Cell Rev Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ol.2018.9583","article-title":"Patient-derived xenograft mouse models: a high-fidelity tool for individualized medicine","volume":"17","author":"Xu","year":"2019","journal-title":"Oncol Lett"},{"key":"B12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.14348\/molcells.2016.2350","article-title":"An integrative approach to precision cancer medicine using patient-derived xenografts","volume":"39","author":"Cho","year":"2016","journal-title":"Mol Cells"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1538\/expanim1978.29.1_1","article-title":"Breeding of a non-obese, diabetic strain of mice","volume":"29","author":"Makino","year":"1980","journal-title":"Jikken Dobutsu"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.154.1.180","article-title":"Multiple defects in innate and adaptive immunologic function in NOD\/LtSz-scid mice","volume":"154","author":"Shultz","year":"1995","journal-title":"J Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-540-75647-7_1","article-title":"Basic concept of development and practical application of animal models for human diseases","volume":"324","author":"Nomura","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.05.022","article-title":"Ovarian and cervical cancer patient derived xenografts: The past, present, and future","volume":"138","author":"Boone","year":"2015","journal-title":"Gynecol Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"8542","DOI":"10.1038\/srep08542","article-title":"Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer","volume":"5","author":"Zhu","year":"2015","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3390\/cells8060585","article-title":"Establishment of novel gastric cancer patient-derived xenografts and cell lines: pathological comparison between primary tumor, Patient-Derived, and Cell-Line Derived Xenografts","volume":"8","author":"Kuwata","year":"2019","journal-title":"Cells"},{"key":"B19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12935-017-0497-4","article-title":"Establishment and evaluation of four different types of patient-derived xenograft models","volume":"17","author":"Ji","year":"2017","journal-title":"Cancer Cell Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.985154","article-title":"Patient-derived xenograft models for gastrointestinal tumors: A single-center retrospective study","volume":"12","author":"Yu","year":"2022","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.08.041","article-title":"A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds","volume":"167","author":"Bruna","year":"2016","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nature.2016.19364","article-title":"US cancer institute to overhaul tumour cell lines","volume":"530","author":"Ledford","year":"2016","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.140","article-title":"Interrogating open issues in cancer precision medicine with patient-derived xenografts","volume":"17","author":"Byrne","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0761","article-title":"Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs","volume":"74","author":"Pennacchietti","year":"2014","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ygyno.2004.09.025","article-title":"Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models","volume":"96","author":"Lee","year":"2005","journal-title":"Gynecol Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"22172","DOI":"10.1038\/srep22172","article-title":"Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer","volume":"6","author":"Choi","year":"2016","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11304","article-title":"Prognostic impact of CD163+ macrophages in tumor stroma and CD8+ T-Cells in cancer cell nests in invasive extrahepatic bile duct cancer","volume":"37","author":"Miura","year":"2017","journal-title":"Anticancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-317685","article-title":"The relationship between tissue factor and cancer progression: insights from bench and bedside","volume":"119","author":"van den Berg","year":"2012","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1412827","article-title":"Non-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients","volume":"11","author":"Ferrer","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10517-019-04618-6","article-title":"Antimicrobial effect of albumin on bacteria and yeast cells","volume":"167","author":"Arzumanyan","year":"2019","journal-title":"Bull Exp Biol Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12967-019-02177-y","article-title":"A spontaneously metastatic model of bladder cancer: imaging characterization","volume":"17","author":"Tatum","year":"2019","journal-title":"J Transl Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2018.11.009","article-title":"Non-invasive dynamic monitoring initiation and growth of pancreatic tumor in the LSL-Kras; LSL-Trp53; Pdx-1-Cre (KPC) transgenic mouse model","volume":"465","author":"Hu","year":"2019","journal-title":"J Immunol Methods"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2013.03.004","article-title":"A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins","volume":"7","author":"Keysar","year":"2013","journal-title":"Mol Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"117101","DOI":"10.1016\/j.bcp.2025.117101","article-title":"Therapeutic potential of HDAC inhibitors in a xenograft model of cancers: A special focus on breast cancer","volume":"240","author":"Pancholi","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003480","article-title":"Patient-derived xenograft model: Applications and challenges in liver cancer","volume":"138","author":"Dou","year":"2025","journal-title":"Chin Med J (Engl)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00779-3","article-title":"PDX models for functional precision oncology and discovery science","volume":"25","author":"Blanchard","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.06.110","article-title":"Ki67 is a graded rather than a binary marker of proliferation versus quiescence","volume":"24","author":"Miller","year":"2018","journal-title":"Cell Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1683916\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:29:21Z","timestamp":1762428561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1683916\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2025.1683916"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1683916","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"article-number":"1683916"}}